Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
See this article on SinglePoint?
https://www.proactiveinvestors.com/companies/news/989605/singlepoint-expects-immediate-revenue-opportunities-for-its-majority-owned-subsidiary-boston-solar-with-passage-of-the-inflation-reduction-act-989605.html
It has been frustrating to see all those other solar energy stocks ramping up in price and volume and SING doing NADA until just yesterday. Kind of wish the "S" in SING stood for Solar. LOL
$SIRC was in a great post on Reddit
https://www.reddit.com/r/pennystocks/comments/wgxeb7/one_by_onesolar_stock_are_rocking_today_it_is/
Anyone see this on Reddit? SinglePoint is mentioned along with other solar energy stocks. But it does note that $SING is way undervalued at this price.
Question is--what will make it move up like all the other solar stocks?
https://www.reddit.com/r/pennystocks/comments/wgxeb7/one_by_onesolar_stock_are_rocking_today_it_is/
SING chart sure woke up today
[chaft]www.stockscores.com/chart.asp?TickerSymbol=sing&TimeRange=90&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=None&Band=BB&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=MACD&Indicator2=MACD&Indicator3=FStoch&Indicator4=RSI&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen%5B/img%5D[/chart]
Got this from the company. Missed it when it first came out... Seems like
they are really expecting to get some contracts. And even the difficult
question of the up listing to NASDAQ is addressed
https://www.visiumtechnologies.com/faq-frequently-asked-questions
Watching this one for news of a contract....
Very good point! Hospitals too, thinking of chemotherapy centers
SING's BOX Pure Air tweeted this out. Social media marketing is not being neglected, apparently.
With all that Fed funding, SING should be getting more news flow from air purification contracts.
insert-text-here
Is there anything positive about this company that may make me want to buy a bit?
Splunk Has Never Been A Better Bargain
Jun. 30, 2022
Summary
Shares of Splunk look incredibly attractive at a ~5x forward revenue multiple, after losing 20% of its value year to date.
The company continues to achieve stellar >30% y/y revenue growth, driven by the maturity in its cloud transition.
Gross margins and operating margins are also trending upward, and the company just boosted its full-year outlook.
Splunk plays in a massive $100 billion TAM and has a history of strong execution, especially with its new CEO who used to lead sales.
insert-text-here
I understand the frustration - I know so many people that have been waiting a long time for numbers to move. I sincerely say that your waiting is well worth it
Great article on the renewables market sector, from Barron's
insert-text-here
Worth a read, IMO.
This is looking too good to pass up - let's see what happens tomorrow....!
Very exciting! Good things just take a little time!
VISM CEO Interview
Thank you for this summary - I am keeping my eyes on this. I like how broad of a spectrum $XELA has its hands on....
I think he is cool, yes a huge pull in that demographic - I'm looking forward to what $IPSI does with this kind of media converge
Aethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment
https://d1io3yog0oux5.cloudfront.net/_29959e27d7a01d508073adc278ab5d61/aethlonmedical/news/2022-07-11_Aethlon_Medical_Announces_U_S_FDA_Approval_of_448.pdf
July 11, 2022
Approval eliminates the requirement for previous dialysis treatment, potentially enabling accelerated enrollment in the ongoing clinical study
SAN DIEGO, July 11, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an amendment to the protocol of its ongoing clinical trial investigating the Aethlon Hemopurifier® for patients with severe COVID-19. The newly approved protocol amendment eliminates the inclusion criteria that patients must have a dialysis catheter in place and have tolerated dialysis at the time of screening.
"We are pleased that the FDA has approved our protocol amendment for the COVID-19 trial," said Charles J. Fisher, Jr., M.D., Chief Executive Officer of Aethlon Medical. "We anticipate that this protocol amendment will enable us to enroll patients at an increased rate now that dialysis treatment is no longer a study requirement. We look forward to providing access to this potentially life-saving therapy to patients in need."
The Aethlon Hemopurifier is a therapeutic blood filtration system that can bind and remove life-threatening viruses and harmful exosomes from blood. Aethlon is currently evaluating the safety and feasibility of the Hemopurifier in an active Early Feasibility Study (EFS), analogous to a Phase 1 clinical trial for a drug or biologic, which is designed to enroll up to 40 severe COVID-19 patients [NCT04595903]. Aethlon recently announced that the first patient has completed Hemopurifier treatment in the trial and that there are nine hospitals actively screening patients.
"We have learned from our study sites during screening, from data presentations and from thought leaders in the field that the incidence of COVID-19-induced kidney injury, resulting in the need for kidney replacement therapy (KRT), has decreased dramatically during the course of the pandemic," said Steven LaRosa, M.D., Chief Medical Officer of Aethlon Medical. "As such, we worked closely with the FDA to construct updated wording in the protocol and informed consent that allows patients to participate in the study who do not already require KRT yet still protects patient safety."
"This protocol amendment will need to be submitted by the investigative teams and approved by the IRB at each clinical site; a process that can take several months. It also remains to be seen if the prevailing COVID-19 variant BA.5 will result in increased ICU admissions; a requirement of the clinical study," continued Dr. LaRosa.
Aethlon is working with PPD, Inc., an established contract research organization (CRO), to advance this clinical study.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical technology company developing the Hemopurifier, a therapeutic blood filtration system indicated for infectious diseases and cancer. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Under an Investigational Device Exemption (IDE) application, the FDA approved a single site, open-label Early Feasibility Study (EFS) to evaluate the Hemopurifier for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The EFS is being conducted at the University of Pittsburgh Medical Center Hillman Cancer Center.
The Hemopurifier also holds an FDA Breakthrough Device designation and an open IDE application related to the treatment of life-threatening viruses that are not addressed with approved therapies. A recent amendment to the IDE enabled Aethlon to implement a new EFS protocol to treat up to 40 COVID-19 patients at up to 20 clinical sites in the U.S. In two case studies of patients treated under Emergency Use (EU), the Hemopurifier demonstrated binding of SARS-CoV-2 spike protein and removal of SARS-CoV-2 virus from the circulation of a human patient.
Thanks for all this information. Do you know when they normally report their second-quarter financials?
Would I be wrong that if they are going to do $36 million in revenue, not to be too simplistic...but they could do over $8 million in revenue in the second quarter? That would surprise many investors, IMO.
I would not be surprised to see this retrace by 50% on this move today. And the chart would still be positive if it did so.
These biotech companies are starting to act much better when they have good news, I have six biotech stocks and every one of them is up! We may have seen the bottom in biotech
I may have picked the bottom! Looking for a double in twelve months!
It seems that investing in VISM right now requires a great deal of trust and confidence that TruContext contracts are forthcoming. The stock is beaten down, IMO, because everyone knows that the company is raising capital and doing a reverse to go to NASDAQ. That also means they already have investors that have the confidence that contracts are coming...what do you think Eagle1?
Looks like I got in at a good time a few days ago. Great chart. Would
like to see more volume, but this has gotten slammed in the past couple
of months for no real reason other than some investors see them as a
crypt miner. I, too, asked for info from the company and got the list of
things to consider. They may be getting more active in getting their
story out before their Second Quarter filing.
IF the company announces a contract or two, will that change your mind about their technology being a "me too" product? I would think that contract would confirm that the technology adds something to a customer's cyber security defense.
Let's breathe this back to life...telecommunication should be thriving with the use of social media, I am saying this overall because of our access to so much.
That is frustrating. Any response from them for your effort goes a long way...!
Cricket...cricket....I thought this was one to keep an eye on this year.
Right!!! Seeing that arrow pointing UP! = :)
OLB is in this video
I saw this posted on YouTube, if they can convert their technology into actual sales this could really fly. It is so undervalued now but understandable with no revenue yet! It looks like they have partners that can help with the sales, bottom line, high risk, high potential return
FWIW
These biotechs can really run when they have good news. Biotechs have been really beaten down lately...
I hope it drops back a bit. I never liked to buy a runner like this unless it consolidates off today's high
Most investors who still want to be in the market feel more comfortable owning a Blue Chip stock for the eventual turnaround because you know they will not go bankrupt. F is one of those names, at some point when people feel more comfortable they will bid up these Blue Chips. If you have a long time horizon, IMO, we will see Ford back to $20 within 12 to 18 months